Role of the T-type calcium channel in cardiac myocyte hypertrophy

Lead Research Organisation: King's College London
Department Name: Unlisted

Abstract

Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.

Publications

10 25 50
 
Description KRUK Research Project Grant
Amount £199,657 (GBP)
Funding ID RP39/2014 
Organisation Kidney Research UK 
Sector Charity/Non Profit
Country United Kingdom
Start 09/2015 
End 08/2018
 
Description MRC Clinical PhD Fellowship
Amount £214,119 (GBP)
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 08/2007 
End 07/2010
 
Description T-channels in disease - Tau 
Organisation Tau Therapeutics
Country United States 
Sector Private 
PI Contribution We have on going discussions with them about the use of their compounds to treat cardiovascular disease.
Collaborator Contribution They have provided us with a novel T channel blocking agent which has proved effective in limiting cardiac hypertrophy in cell cultures. It has also lead to testing their compound in a renal model of disease - studies which are ongoing.
Impact This has been a collaboration with Tau Therapeutics. They have contributed by providing reagents and discussion as well as pooling data to try to understand T-channels in cell growth. This has helped as there are few people world-wide working in this area.; They have provided us with a novel T channel blocking agent which has proved effective in limiting cardiac hypertrophy in cell cultures. It has also lead to testing their compound in a renal model of disease - studies which are ongoing.
 
Description T-type channels in neonatal cardiac hypertrophy - Snutch 
Organisation University of British Columbia
Country Canada 
Sector Academic/University 
PI Contribution We are hosting a research fellow from the University of British Columbia in our lab in London. This fellow is paid by a Canadian fellowship but is working in London on a collaborative project.
Collaborator Contribution We have a research fellow funded by a Canadian Fellowship working in my lab in London. This fellow has added to our understanding of the role of T-type channels in cardiac hypertrophy and specifically the ability of PUFA to block both these channels and the ensuing hypertrophy.
Impact A paper is in preparation but no published output as yet.
Start Year 2010
 
Description Hoffman La Roche - marketing slide set 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Type Of Presentation Keynote/Invited Speaker
Geographic Reach International
Primary Audience Health professionals
Results and Impact I designed and produced a slide set explaining T-type channel physiology which Roche's sales representatives then used to explain the concept of the T channel as a therapeutic target. This was distributed to 100's of their sales team. This is no longer in use however as the drug has been withdrawn.

None that I am aware of.
Year(s) Of Engagement Activity 2007,2008
 
Description Hoffman La Roche GP Education 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Type Of Presentation Keynote/Invited Speaker
Geographic Reach National
Primary Audience Health professionals
Results and Impact Gave over 30 lectures around the country to GPs and other front-line health professionals on the physiology and pathophysiology of T-type Ca channels.

I was also subsequently asked to run 3 training days educating Hoffman La Roche's sales team about T-type Ca channels.
Year(s) Of Engagement Activity 2006,2007,2008
 
Description Hoffman La Roche UK Advisory Board 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Health professionals
Results and Impact This was entirely limited to 'industrial' engagement i.e. convincing Hoffman La Roche of the advantages of basic science and approaching clinical problems by understanding pre-clinical physiology.

None
Year(s) Of Engagement Activity 2006,2007,2008
 
Description Hoffman La Roche promotional video 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Type Of Presentation Keynote/Invited Speaker
Geographic Reach International
Primary Audience Other academic audiences (collaborators, peers etc.)
Results and Impact I made a promotional video for use by Hoffman La Roche's marketing department to promote the idea of T-type Ca channels as therapeutic targets in disease. This video would have been used by them to target other healthcare professionals. Since their drug has now been withdrawn, it will no longer be used.

None that I know of.
Year(s) Of Engagement Activity 2007
 
Description Tau Therapeutics Expert Advisory Board 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? Yes
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Presented work to Tau Pharmaceuticals Expert Advisory Board in the USA

Continued collaboration.
Year(s) Of Engagement Activity 2006